Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: Effectiveness and safety results from an open-label study

Journal of Rheumatology

Volumn 37, Issue 9, 2010, Pages 1898-1906

  Gladman, Dafna D ^a   Sampalis, John S ^b,c   Illouz, Olivier ^d,e   Guérette, Benoît ^d,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b JSS Medical Research   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d ABBOTT LABORATORIES   (United States)

^e Abbott   (France)

Author keywords

Adalimumab; Biologics; Clinical trial; Psoriatic arthritis; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIRHEUMATIC AGENT; CORTICOSTEROID; EFALIZUMAB; ETANERCEPT; METHOTREXATE; PSORALEN; RETINOID; VITAMIN D DERIVATIVE;

ADULT; ADVERSE DRUG REACTION; ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTHESITIS; FEMALE; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RATING SCALE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CANADA; DISABILITY EVALUATION; FEMALE; HUMANS; JOINTS; MALE; MIDDLE AGED; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SKIN; TREATMENT OUTCOME;

EID: 77956478012     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.100069     Document Type: Article

References (25)

1. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course and outcome. Ann Rheum Dis 2005;64 Suppl II:ii14-7.
2. Kane D, Stafford L, Bresnihan B, Fitzgerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 2003;42:1460-8. (Pubitemid 37508919)
3. Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997;6:1349-56.
4. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998;25:1544-52.
5. Anandarajah AP, Ritchlin C. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 2004;16:338-43.
6. Mease P. TNF therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 2004;63:755-8.
7. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7.
8. Mease PJ, Kivitz AJ, Burch FX, Seigel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis, safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
9. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al; Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
10. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JYM, et al; Psoriasis Work Group. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guideline of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64.
11. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
12. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
13. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013-20.
14. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
15. Walker N, Michaud K, Wolfe F. Work limitations among persons with rheumatoid arthritis: results, reliability and validity of the Work Limitations Questionnaire in 836 patients. J Rheumatol 2005;32:1006-12.
16. Gladman DD, Sampalis JS, Martel MJ, Gooch KL, Wong RL, Guérette B. Reliability and validity of the Work Limitations Questionnaire and impact of adalimumab (HUMIRA®) on presenteeism for patients with psoriatic arthritis (PsA): Results of ACCLAIM [abstract]. Arthritis Rheum 2008;58 Suppl:S202.
17. Gladman DD, Tom BD, Mease PJ, Farewell VT. Response criteria for psoriatic arthritis II: Developing and comparing response criteria for PsA. Ann Rheum Dis 2008;67 Suppl II:526.
18. Gladman DD, Psaradellis F, Illouz O, Sampalis JS. Evaluation of response using the Psoriatic Arthritis Joint Activity Index scoring tool in patients treated with adalimumab: Post-hoc analysis of the ACCLAIM study [abstract]. J Rheumatol 2009;36:2571.
19. van den Bosch F, Manger B, Goupille P, McHugh N, Rødevand E, Holck P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis (PsA) and predictors of good clinical responses for arthritis, skin, and nail lesions. Ann Rheum Dis 2010;69:394-9.
20. van Vollenhoven RF. Switching between biological agents. Clin Exp Rheum 2004;22 Suppl 35:S115-21.
21. Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, et al; Research in Active Rheumatoid Arthritis (ReAct) Study Group. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 2007;46:1191-9.
22. Burmester G-R, Kary S, Unnebrink K, Guerette B, Oezer U, Kupper H. Three-year effectiveness of adalimumab in patients with rheumatoid arthritis with and without history of other tumor necrosis factor-antagonist therapies [abstract]. Arthritis Rheum 2009;60 Suppl:S628.
23. Rudwaleit M, Claudepierre P, Wordsworth P, Loza Cortina E, Sieper J, Kron M, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009;36:801-8.
24. Burmester GR, Rudwaleit M, van den Bosch F, Kron M, Kary S, Kupper H. Adalimumab (HUMIRA®) therapy is effective and well-tolerated in ankylosing spondylitis (AS), rheumatoid arthritis (RA), or psoriatic arthritis (PsA) patients with a history of anti-TNF therapy [abstract]. Ann Rheum Dis 2008;67 Suppl II:177.
25. Mease PJ, Ganguly R, Wanke L, Yu E, Singh A. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) group guidelines. Ann Rheum Dis 2004;63 Suppl:391-2.